Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet

SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical obtained approval for a SGLT-2 inhibitor+metformin combination drug in just one month after the release of Envlo Tab., the 1st SGLT-2 inhibitor by Korea, expanding its product portfolio. Daewoong Pharmaceutical (Jeon Sen...

2023-07-19 08:52 1932

First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib

MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstad...

2023-07-19 05:00 2039

Join Taipei City's Thriving Health Industry: Registration for "Win A Greater Health" Pitch Contest Starts Now!

TAIPEI, July 18, 2023 /PRNewswire/ -- The Taipei City Government's Department of Economic Development is taking proactive steps to attract international startups and foster collaboration with local businesses through its "Talent Exchange Program". In line with this initiative, they have establish...

2023-07-18 11:35 1633

Join Taipei City's Thriving Health Industry: Registration for

Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States

- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop, commercialize, and manufacture ATG-017 - The combination portion of the ERASER study, the first-in-human (FIH) study of ATG-017, was designed to evaluate the safety/tole...

2023-07-18 08:30 2024

ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023

AMSTERDAM, July 17, 2023 /PRNewswire/ -- The data reported today by Eli Lilly from theTRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer's disease demonstrate an important advancement in Alzheimer's research and treatment. The full Phase 3 data was reported at the Alzh...

2023-07-17 21:15 1869

Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong * XPOVIO® has received regulatory approvals in 41 countries and regions includingthe United States, Israel, the United Kingdom, the European Union (the 27 member countries includingFrance and Italy), Canada, Norw...

2023-07-17 08:30 2390

Red Marrow Peptide-A Major Breakthrough in Human Health Engineering

BEIJING, July 14, 2023 /PRNewswire/ -- 1.8 g! This figure refers to the weight of red marrow which can be extracted from a 100 kg young yak growing in no-human zone ofQinghai and enjoys the reputation of "the key of cardiovascular health". It is called the most perfect "blood scavenger", ...

2023-07-14 12:51 1811

Menarini Silicon Biosystems announces the launch of its new CELLSEARCH® CTC test with the DLL3 biomarker for small cell lung cancer

This new CELLSEARCH Circulating Tumor Cell (CTC) test is now available as a Research Use Only (RUO) lab service inNorth America and Europe. It is currently intended for basic and pharmaceutical research and it is the latest example of how Menarini Silicon Biosystems continues its development of c...

2023-07-13 20:00 2666

Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences

HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, hereby...

2023-07-12 20:45 2365

Raya Therapeutic announces early-stage R&D collaboration with argenx

MONTREAL, July 12, 2023 /PRNewswire/ -- Raya Therapeutic Inc., ("Raya") a mission-driven company focused on the treatment of neurodegenerative diseases, has entered into an early-stage R&D collaboration with argenx. The collaboration focuses on testing combinations of Raya's pipeline of targeted ...

2023-07-12 19:07 2084

Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation

SINGAPORE, July 12, 2023 /PRNewswire/ -- On July 6, 2023, Biosyngen received an official notification from the U.S. Food and Drug Administration (FDA) granting Fast Track Designation (FTD) to its revolutionary first-in-class immunotherapy, BRG01, for the treatment of relapsed/metastatic nasophary...

2023-07-12 13:38 2689

Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

SINGAPORE, July 12, 2023 /PRNewswire/ -- This is a model of cooperation between Singapore and China, more importantly, working jointly in the area of research and development. Through this initiative, China Singapore Knowledge City paths the way to attract both local and overseas therapeutic asse...

2023-07-12 10:32 2560

Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism

HANGZHOU, China and SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characteriza...

2023-07-12 10:00 2051

GI Dynamics Announces Company Rebrand as Morphic Medical® Reintroducing Flagship Product as RESET®

BOSTON, July 11, 2023 /PRNewswire/ -- GI Dynamics, creator of the world's first medical device designed to target the underlying cause of type 2 diabetes, is proud to announce its rebrand to Morphic Medical and the introduction of RESET, formally known as EndoBarrier®. This transformative shift r...

2023-07-12 07:12 2000

Race executes global license agreement with City of Hope to access FTO IP

* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...

2023-07-11 07:30 1998

Rx-360 Expands Trademark Portfolio to Japan

PHILADELPHIA, July 10, 2023 /PRNewswire/ -- Rx-360 is pleased to announce that the consortium has now expanded their trademark registration for Joint Audit Program® logo to now include Japan. Through the achievement of this milestone, Rx-360 has secured trademark registration for Rx360 and the J...

2023-07-10 18:00 1594

Calling Bright Minds in Southeast Asia, Bio Farma and MIT Hacking Medicine is Set to Revolutionize Healthcare with a 4-Day Hackathon

JAKARTA, Indonesia, July 10, 2023 /PRNewswire/ -- Bio Farma , Indonesia's state-owned Pharmaceutical company, is collaborating with MIT Hacking Medicine to address urgent healthcare challenges in the region by holding the first-everBio Farma x MIT Hacking Medicine Ha...

2023-07-10 15:19 2496

Calling Bright Minds in Southeast Asia, Bio Farma and MIT Hacking Medicine is Set to Revolutionize Healthcare with a 4-Day Hackathon

RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes YANTAI, China, July 10, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fu...

2023-07-10 10:24 2041

Kexing Biopharm Makes it into China's Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years

SHENZHEN, China, July 7, 2023 /PRNewswire/ -- Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized onJune 27 as one of "China's Top 20 Biopharmaceutical Enterprises" (blood products, vaccines and insulin) for two consecutive years. This prestigious sub-lis...

2023-07-07 19:43 4171

Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)

SUZHOU, China, July 7, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has received ...

2023-07-07 15:52 2545

1 ... 26 27 282930 31 32 ... 181